SMAD4 and pancreatic neoplasm: GEMMs incorporating Smad4 deletion alongside KrasG12D expression, such as Pdx1-CreLSL-KrasG12DSmad4lox/lox, exhibit robust tumor progression and desmoplastic stromal responses, hallmarks of human pancreas cancer (112, 113).